Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) saw strong trading volume on Friday . 307,662 shares were traded during trading, an increase of 147% from the previous session’s volume of 124,554 shares.The stock last traded at $155.90 and had previously closed at $155.02.

A number of analysts recently commented on the company. Jefferies Group reiterated a “buy” rating on shares of Bio-Rad Laboratories in a report on Wednesday, June 8th. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th.

The stock has a 50 day moving average price of $143.92 and a 200-day moving average price of $138.99. The stock has a market capitalization of $4.58 billion and a price-to-earnings ratio of 42.63.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, August 3rd. The company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.13 by $0.52. The business earned $516.80 million during the quarter, compared to analysts’ expectations of $497.80 million. During the same quarter last year, the business earned $0.97 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts predict that Bio-Rad Laboratories Inc. will post $3.10 EPS for the current fiscal year.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Levin Capital Strategies L.P. increased its position in Bio-Rad Laboratories by 9.5% in the fourth quarter. Levin Capital Strategies L.P. now owns 689,214 shares of the company’s stock worth $95,566,000 after buying an additional 60,059 shares during the period. Morgan Stanley increased its position in Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock worth $9,921,000 after buying an additional 55,884 shares during the period. BlackRock Advisors LLC increased its position in Bio-Rad Laboratories by 4.7% in the fourth quarter. BlackRock Advisors LLC now owns 114,344 shares of the company’s stock worth $15,855,000 after buying an additional 5,085 shares during the period. Liberty Mutual Group Asset Management Inc. increased its position in Bio-Rad Laboratories by 51.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,320 shares of the company’s stock worth $1,846,000 after buying an additional 4,523 shares during the period. Finally, Principal Financial Group Inc. increased its position in Bio-Rad Laboratories by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 66,434 shares of the company’s stock worth $9,212,000 after buying an additional 2,238 shares during the period.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.